Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia.

Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia.

Detalles Bibliográficos
Autor Principal:	Armitage, J
Formato:	Journal article
Idioma:	English
Publicado:	2008

Títulos similares

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
por: Minhas, R, et al.
Publicado: (2009)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
por: Neil, A, et al.
Publicado: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
por: Neil, H, et al.
Publicado: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
por: Neil, H, et al.
Publicado: (2004)

CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosis
por: M. Doortje Reijman, et al.
Publicado: (2024-03-01)

Commentary: What's so special about familial hypercholesterolaemia?
por: Mant, D
Publicado: (2009)

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation
por: R Ara, et al.
Publicado: (2008-05-01)

Familial hypercholesterolaemia.
por: Gill, P, et al.
Publicado: (2012)

Familial hypercholesterolaemia
por: D.J. Blom
Publicado: (2011-01-01)

Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis
por: Jennifer Cox, et al.
Publicado: (2019-07-01)

Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective
por: Gerald F. Watts, et al.
Publicado: (2021-06-01)

Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis.
por: Arambepola, C, et al.
Publicado: (2007)

Statins and familial hypercholesterolaemia.
por: Neil, A, et al.
Publicado: (2009)

Commentary: Controversies in NICE guidance on chronic kidney disease.
por: Landray, M, et al.
Publicado: (2008)

Commentary: Controversies in NICE guidance on chronic kidney disease
por: Landray, M, et al.
Publicado: (2008)

Risk factors for cardiovascular events in patients with heterozygous familial hypercholesterolaemia: protocol for a systematic review
por: Jing Pang, et al.
Publicado: (2023-03-01)

Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review
por: Noor Shafina Mohd Nor, et al.
Publicado: (2019-04-01)

The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia.
por: Pitsavos, C, et al.
Publicado: (2009)

EASILY MISSED? Familial hypercholesterolaemia
por: Gill, P, et al.
Publicado: (2012)

Commentary: NICE guidance on antibiotic prescribing for self limiting respiratory tract infections in primary care
por: Butler, C, et al.
Publicado: (2008)

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*
por: Borislav Borissov, et al.
Publicado: (2017-01-01)

Familial Hypercholesterolaemia: An Updated Overall Management
por: Mohd Kasim, Noor Alicezah, et al.
Publicado: (2020)

Novel molecular therapies for the treatment of familial hypercholesterolaemia
por: Kerr, A
Publicado: (2016)

Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.
por: Neil, H, et al.
Publicado: (2003)

Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
por: Neil, H, et al.
Publicado: (2005)

The impact of rarity in NICE’s health technology appraisals
por: Sophie Clarke, et al.
Publicado: (2021-05-01)

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
por: Vallejo-Vaz, Antonio J., et al.
Publicado: (2020)

Commentary: Controversies in NICE guidance on antibiotic prescribing for self limiting respiratory tract infections in primary care.
por: Butler, C, et al.
Publicado: (2008)

International Atherosclerosis Society Roadmap for Familial Hypercholesterolaemia
por: Gerald F. Watts, et al.
Publicado: (2024-01-01)

Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis
por: Anastasia V. Poznyak, et al.
Publicado: (2022-10-01)

Dietary intervention for children and adolescents with familial hypercholesterolaemia
por: Maria Elena Capra, et al.
Publicado: (2023-06-01)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
por: Neil, A, et al.
Publicado: (2008)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
por: Neil, A, et al.
Publicado: (2008)

Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group.
por: Neil, H, et al.
Publicado: (1999)

Low-density lipoprotein receptor-negative compound heterozygous familial hypercholesterolaemia: case study with follow-up over 23 years
por: C. van Heyningen, et al.
Publicado: (2022-10-01)

NICE and new: appraising innovation.
por: Ferner, R, et al.
Publicado: (2010)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
por: Marks, D, et al.
Publicado: (2000)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
por: Marks, et al.
Publicado: (2000-01-01)

A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.
por: Marks, D, et al.
Publicado: (2003)

How do the experiences and beliefs of adults and children with heterozygous familial hypercholesterolaemia influence their adherence to treatment? A systematic review of qualitative evidence protocol
por: Fiona J. Kinnear, et al.
Publicado: (2018-08-01)